Repro Med Company Insiders

KRMD Stock  USD 3.43  0.15  4.19%   
Repro Med's insiders are aggressively buying. The analysis of insiders' sentiment of trading Repro Med Systems stock suggests that all insiders are extremely bullish at this time. Repro Med employs about 82 people. The company is managed by 8 executives with a total tenure of roughly 192 years, averaging almost 24.0 years of service per executive, having 10.25 employees per reported executive.

Insider Sentiment 100

 Aggressively Buying

 
Selling
 
Buying

Latest Trades

2023-08-21Joseph M Jr. MankoAcquired 10000 @ 2.65View
2023-08-18Linda M TharbyAcquired 5272 @ 2.53View
2023-08-16Robert CascellaAcquired 19000 @ 2.61View
2022-05-12Joseph M Jr. MankoAcquired 20000 @ 2.01View
Monitoring Repro Med's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Repro Med Systems. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Repro Med's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Repro Med's future performance. Based on our forecasts, it is anticipated that Repro will maintain a workforce of about 80 employees by March 2025.
 
Credit Downgrade
 
Yuan Drop
 
Covid

Repro Med Management Team Effectiveness

The company has return on total asset (ROA) of (0.1405) % which means that it has lost $0.1405 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5301) %, meaning that it created substantial loss on money invested by shareholders. Repro Med's management efficiency ratios could be used to measure how well Repro Med manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.42. The current year's Return On Capital Employed is expected to grow to -0.37. At present, Repro Med's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 93.5 K, whereas Return On Tangible Assets are projected to grow to (0.42).
As of February 27, 2025, Common Stock Shares Outstanding is expected to decline to about 37.4 M. The current year's Net Loss is expected to grow to about (7.4 M)

Repro Med Workforce Comparison

Repro Med Systems is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 87,403. Repro Med adds roughly 82.0 in number of employees claiming only tiny portion of equities under Health Care industry.

Repro Med Profit Margins

The company has Profit Margin (PM) of (0.37) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.21) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.21.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.460.53
Fairly Down
Slightly volatile

Repro Med Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Repro Med insiders, such as employees or executives, is commonly permitted as long as it does not rely on Repro Med's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Repro Med insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
2.3333
7
3
 1,373,601 
 2,016,187 
2024-09-01
3.4
17
5
 589,474 
 996,277 
2024-03-01
2.3333
7
3
 60,819 
 488,025 
2023-12-01
2.75
11
4
 1,154,948 
 2,294,152 
2023-09-01
4.0
12
3
 474,553 
 300,000 
2023-03-01
6.0
12
2
 74,629 
 733,989 
2022-09-01
2.0
6
3
 43,427 
 200,000 
2022-06-01
3.3333
10
3
 541,901 
 216,224 
2022-03-01
5.0
10
2
 81,041 
 150,210 
2021-12-01
10.0
10
1
 110,000 
 62,500 
2021-06-01
3.25
13
4
 1,045,291 
 1,021,275 
2020-12-01
6.6667
20
3
 203,043 
 164,420 
2020-06-01
3.0
9
3
 541,681 
 562,844 
2020-03-01
2.5
10
4
 584,928 
 702,860 
2019-09-01
2.6667
8
3
 1,105,443 
 1,145,000 
2019-06-01
5.25
21
4
 1,218,820 
 65,000 
2018-12-01
4.4286
31
7
 4,162,601 
 10,198,060 
2018-09-01
9.0
18
2
 1,226,428 
 1,000,000 
2018-06-01
14.0
14
1
 104,932 
 0.00 
2017-12-01
23.0
23
1
 1,040,213 
 95,000 
2017-06-01
2.25
9
4
 126,417 
 53,983 
2017-03-01
16.0
32
2
 387,687 
 500,000 
2013-06-01
1.0
1
1
 10,000 
 73,000 
2012-03-01
1.0
1
1
 40,000 
 0.00 
2009-06-01
2.0
2
1
 2,000,000 
 500,000 

Repro Med Notable Stakeholders

A Repro Med stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Repro Med often face trade-offs trying to please all of them. Repro Med's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Repro Med's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Linda TharbyCEO PresidentProfile
Brian CaseChief OfficerProfile
Thomas AdamsChief OfficerProfile
Rob CannonVice SalesProfile
Josh BennettVP DevelProfile
Kenneth MillerChief OfficerProfile
Tom AdamsInterim OfficerProfile
Christopher PazdanSenior OperationsProfile

About Repro Med Management Performance

The success or failure of an entity such as Repro Med Systems often depends on how effective the management is. Repro Med management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Repro management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Repro management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.45)(0.42)
Return On Capital Employed(0.39)(0.37)
Return On Assets(0.43)(0.41)
Return On Equity(0.61)(0.58)
Please note, the presentation of Repro Med's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Repro Med's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Repro Med's management manipulating its earnings.

Repro Med Workforce Analysis

Traditionally, organizations such as Repro Med use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Repro Med within its industry.

Repro Med Manpower Efficiency

Return on Repro Med Manpower

Revenue Per Employee347.8K
Revenue Per Executive3.6M
Net Loss Per Employee167.6K
Net Loss Per Executive1.7M
Working Capital Per Employee192.7K
Working Capital Per Executive2M

Complementary Tools for Repro Stock analysis

When running Repro Med's price analysis, check to measure Repro Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repro Med is operating at the current time. Most of Repro Med's value examination focuses on studying past and present price action to predict the probability of Repro Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repro Med's price. Additionally, you may evaluate how the addition of Repro Med to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets